238 related articles for article (PubMed ID: 36934104)
1. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
[TBL] [Abstract][Full Text] [Related]
2. FBXW7: a critical tumor suppressor of human cancers.
Yeh CH; Bellon M; Nicot C
Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
[TBL] [Abstract][Full Text] [Related]
3. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
[TBL] [Abstract][Full Text] [Related]
4. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation.
Kanei-Ishii C; Nomura T; Takagi T; Watanabe N; Nakayama KI; Ishii S
J Biol Chem; 2008 Nov; 283(45):30540-8. PubMed ID: 18765672
[TBL] [Abstract][Full Text] [Related]
5. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
6. Recent insight into the role of FBXW7 as a tumor suppressor.
Yumimoto K; Nakayama KI
Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
[TBL] [Abstract][Full Text] [Related]
7. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract][Full Text] [Related]
8. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination.
Zhu H; Wang X; Zhou X; Lu S; Gu G; Liu C
Lab Invest; 2022 Nov; 102(11):1203-1213. PubMed ID: 35840806
[TBL] [Abstract][Full Text] [Related]
9. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
[TBL] [Abstract][Full Text] [Related]
10. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Morrugares R; Correa-Sáez A; Moreno R; Garrido-Rodríguez M; Muñoz E; de la Vega L; Calzado MA
Cell Mol Life Sci; 2020 Jul; 77(13):2621-2639. PubMed ID: 31605148
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.
King B; Trimarchi T; Reavie L; Xu L; Mullenders J; Ntziachristos P; Aranda-Orgilles B; Perez-Garcia A; Shi J; Vakoc C; Sandy P; Shen SS; Ferrando A; Aifantis I
Cell; 2013 Jun; 153(7):1552-66. PubMed ID: 23791182
[TBL] [Abstract][Full Text] [Related]
13. The Role of FBXW7 in Gynecologic Malignancies.
Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
Cells; 2023 May; 12(10):. PubMed ID: 37408248
[TBL] [Abstract][Full Text] [Related]
14. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
Asnafi V; Buzyn A; Le Noir S; Baleydier F; Simon A; Beldjord K; Reman O; Witz F; Fagot T; Tavernier E; Turlure P; Leguay T; Huguet F; Vernant JP; Daniel F; Béné MC; Ifrah N; Thomas X; Dombret H; Macintyre E
Blood; 2009 Apr; 113(17):3918-24. PubMed ID: 19109228
[TBL] [Abstract][Full Text] [Related]
15. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
[TBL] [Abstract][Full Text] [Related]
16. Tumor-suppressor Fbxw7 targets SIK2 for degradation to interfere with TORC2-AKT signaling in pancreatic cancer.
Zhang MX; Wang H; Sun GP
Cell Biol Int; 2020 Sep; 44(9):1900-1910. PubMed ID: 32437091
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
Tu K; Zheng X; Zhou Z; Li C; Zhang J; Gao J; Yao Y; Liu Q
PLoS One; 2013; 8(7):e68574. PubMed ID: 23840897
[TBL] [Abstract][Full Text] [Related]
18. The Highs and Lows of FBXW7: New Insights into Substrate Affinity in Disease and Development.
de la Cova CC
Cells; 2023 Aug; 12(17):. PubMed ID: 37681873
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCF
Bajpai S; Jin HR; Mucha B; Diehl JA
Cancer Biol Ther; 2022 Dec; 23(1):348-357. PubMed ID: 35438057
[TBL] [Abstract][Full Text] [Related]
20. Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome.
Stephenson SEM; Costain G; Blok LER; Silk MA; Nguyen TB; Dong X; Alhuzaimi DE; Dowling JJ; Walker S; Amburgey K; Hayeems RZ; Rodan LH; Schwartz MA; Picker J; Lynch SA; Gupta A; Rasmussen KJ; Schimmenti LA; Klee EW; Niu Z; Agre KE; Chilton I; Chung WK; Revah-Politi A; Au PYB; Griffith C; Racobaldo M; Raas-Rothschild A; Ben Zeev B; Barel O; Moutton S; Morice-Picard F; Carmignac V; Cornaton J; Marle N; Devinsky O; Stimach C; Wechsler SB; Hainline BE; Sapp K; Willems M; Bruel AL; Dias KR; Evans CA; Roscioli T; Sachdev R; Temple SEL; Zhu Y; Baker JJ; Scheffer IE; Gardiner FJ; Schneider AL; Muir AM; Mefford HC; Crunk A; Heise EM; Millan F; Monaghan KG; Person R; Rhodes L; Richards S; Wentzensen IM; Cogné B; Isidor B; Nizon M; Vincent M; Besnard T; Piton A; Marcelis C; Kato K; Koyama N; Ogi T; Goh ES; Richmond C; Amor DJ; Boyce JO; Morgan AT; Hildebrand MS; Kaspi A; Bahlo M; Friðriksdóttir R; Katrínardóttir H; Sulem P; Stefánsson K; Björnsson HT; Mandelstam S; Morleo M; Mariani M; ; Scala M; Accogli A; Torella A; Capra V; Wallis M; Jansen S; Weisfisz Q; de Haan H; Sadedin S; ; Lim SC; White SM; Ascher DB; Schenck A; Lockhart PJ; Christodoulou J; Tan TY
Am J Hum Genet; 2022 Apr; 109(4):601-617. PubMed ID: 35395208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
